CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma
New England Journal of Medicine · 13.02.2025 · 392 (7) · 677-685
DOI: 10.1056/nejmoa2309728 ↗Kurz gefasst
Fallbericht in der Zeitschrift New England Journal of Medicine, erschienen am 13.02.2025. Verfasst von Simon J Harrison und 44 weiteren Autor:innen. Beteiligte Einrichtung: Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Multiple Myeloma, Receptors, Chimeric Antigen, B-Cell Maturation Antigen. Die Arbeit wurde bisher 76-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
- Royal Melbourne Hospital, Melbourne, VIC, Australia.
- Translation Laboratory, Centre of Excellence in Cellular Immunotherapy, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia.
- Service d'Hématologie, Centre Hospitalier Universitaire (CHU) Hôtel Dieu, Nantes, France.
- Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, INSERM, Centre National de la Recherche Scientifique, Université d'Angers, Université de Nantes, Nantes, France.
ORCID-Profile: Simon J Harrison, Ing Soo Tiong
Zitieren
APA
Harrison, S. J., Touzeau, C., Kint, N., Li, K., Nguyen, T., Mayeur-Rousse, C., Rahman, M., Le Bris, Y., Er, J., Eugene-Lamer, J., Haynes, N. M., Li, J., Abbott, R. C., Bodet-Milin, C., Moreau, A., Letouzé, E., Lendvai, N., Schecter, J. M., Deraedt, W., …, & Blombery, P. (2025). CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma. New England Journal of Medicine, 392(7), 677-685. https://doi.org/10.1056/nejmoa2309728
Vancouver
Harrison SJ, Touzeau C, Kint N, Li K, Nguyen T, Mayeur-Rousse C, et al. CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma. New England Journal of Medicine. 2025;392(7):677-685. doi:10.1056/nejmoa2309728
BibTeX
@article{Harrison2025,
author = {Harrison, Simon J and Touzeau, Cyrille and Kint, Nicolas and Li, Katherine and Nguyen, Tamia and Mayeur-Rousse, Caroline and Rahman, Marzia and Le Bris, Yannick and Er, Jeremy and Eugene-Lamer, Juliette and Haynes, Nicole M and Li, Jessica and Abbott, Rebecca C and Bodet-Milin, Caroline and Moreau, Anne and Letouzé, Eric and Lendvai, Nikoletta and Schecter, Jordan M and Deraedt, William and Banerjee, Arnob and Lengil, Tamar and Vogel, Martin and Foulk, Brad and Zhao, Hao and Smirnov, Denis and Slaughter, Ana and Lonardi, Carolina and Lee, Erin and Marquez, Loreta and Sankari, Ayah and Plaks, Vicki and Filho, Jose Octavio Costa and Patel, Nitin and Geng, Dong and Gastinne, Thomas and Kelly, Hannah and Tiong, Ing Soo and Eveillard, Marion and Chevallier, Patrice and Lade, Stephen and Moreau, Philippe and Grimmond, Sean and Oliaro, Jane and Tessoulin, Benoit and Blombery, Piers},
title = {CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma},
journal = {New England Journal of Medicine},
year = {2025},
volume = {392},
number = {7},
pages = {677--685},
doi = {10.1056/nejmoa2309728}
}
EUVIMED